Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 12/20 | 0.67 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528249 | 1.00 | GRIA4 (0.67) | GRIA4GRIA2KCNH2NPY5RGRIA1 | |
| SCHEMBL6482318 | 0.88 | GRIA4 (0.53) | GRIA4GRIA2GRIA1GRIA3MTNR1A | |
| SCHEMBL6475868 | 0.84 | GRIA4 (0.48) | GRIA4GRIA2KCNH2NPY5RMTNR1A | |
| SCHEMBL6528247 | 0.84 | GRIA4 (0.48) | GRIA4GRIA2KCNH2NPY5RMTNR1A | |
| SCHEMBL6475291 | 0.82 | GRIA4 (0.62) | GRIA4GRIA2GRIA1GRIA3MTNR1A | |
| SCHEMBL6482156 | 0.82 | MTNR1A (0.52) | GRIA4GRIA2GRIA1GRIA3MTNR1A | |
| SCHEMBL6474389 | 0.82 | GRIA4 (0.62) | GRIA4GRIA2GRIA1GRIA3MTNR1A | |
| SCHEMBL6472657 | 0.81 | GRIA4 (0.47) | GRIA4GRIA2GRIA1GRIA3MTNR1A | |
| SCHEMBL6475304 | 0.81 | GRIA4 (0.47) | GRIA4GRIA2GRIA1GRIA3MTNR1A | |
| SCHEMBL5795330 | 0.80 | GRIA4 (1.00) | GRIA4GRIA2KCNH2NPY5RGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | claimed |
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1265857-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001068592-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225266-A1 | Sulfonamide derivatives | GRIN2A, GRM2, GRIA2 | GRIA4 6/4885GRIA2 3/4885KCNH2 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.